KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Shares Outstanding (2017 - 2025)

Gsk has reported Shares Outstanding over the past 9 years, most recently at $5.7 billion for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.66% year-over-year to $5.7 billion; the TTM value through Dec 2025 reached $5.7 billion, up 3.66%, while the annual FY2025 figure was $5.7 billion, 3.66% up from the prior year.
  • Shares Outstanding for Q4 2025 was $5.7 billion at Gsk, up from $5.5 billion in the prior quarter.
  • Over five years, Shares Outstanding peaked at $7.3 billion in Q4 2021 and troughed at $5.1 billion in Q4 2022.
  • A 5-year average of $5.8 billion and a median of $5.5 billion in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: plummeted 30.36% in 2022 and later grew 5.84% in 2023.
  • Year by year, Shares Outstanding stood at $7.3 billion in 2021, then crashed by 30.36% to $5.1 billion in 2022, then rose by 5.84% to $5.4 billion in 2023, then increased by 3.46% to $5.5 billion in 2024, then grew by 3.66% to $5.7 billion in 2025.
  • Business Quant data shows Shares Outstanding for GSK at $5.7 billion in Q4 2025, $5.5 billion in Q4 2024, and $5.4 billion in Q4 2023.